TY - JOUR
T1 - Eribulin in male patients with breast cancer
T2 - The first report of clinical outcomes
AU - Giotta, Francesco
AU - Acito, Luigi
AU - Candeloro, Giampiero
AU - Del Medico, Pietro
AU - Gadaleta-Caldarola, Gennaro
AU - Giordano, Guido
AU - Gueli, Rossana
AU - Lugini, Antonio
AU - Magri, Valentina
AU - Mandarà, Marta
AU - Masci, Giovanna
AU - Pisconti, Salvatore
AU - Pistelli, Mirco
AU - Rizzi, Anna
AU - Salesi, Nello
AU - Schirone, Alessio
AU - Scognamiglio, Giovanni
AU - Tedeschi, Maria
AU - Zucchinelli, Patrizia
PY - 2016/11/1
Y1 - 2016/11/1
N2 - Background. Evidence on the management and treatment of male breast cancer is scant. We report the analysis of a multicenter Italian series of patients with male breast cancer treated with eribulin. To our knowledge, this is the first report on the use or eribulin in this setting. Patients and Methods. Patients were retrospectively identified in 19 reference centers. All patients received eribulin treatment, according to the standard practice of each center. Data on the identified patients were collected using a standardized form and were then centrally reviewed by two experienced oncologists. Results. A total of 23 patients (median age, 64 yearsrange, 42–80) were considered. The median age at the time of diagnosis of breast cancerwas 57 years (range, 42–74).HER2 status was negative in 14 patients (61%), and 2 patients (9%) had triple-negative disease. The most common metastatic sites were the lung (n 5 1461%) and bone (n 5 1356%). Eribulin was administered for a median of 6 cycles (range, 3–15). All patients reported at least stable diseasetwo complete responses (9%) were documented. Eribulin was well-tolerated, with only four patients (17%) reporting grade 3 adverse events and two (9%) with treatment interruptions because of toxicity. Eight subjects (35%) did not report any adverse event during treatment. For patients with a reported fatal event, the median overall survival from the diagnosis of metastatic disease was 65 months (range, 22–228). Conclusion. Although hampered by all the limitations of any retrospective case series, the results of the present study suggest, for the first time, the use of eribulin as therapy for male breast cancer.
AB - Background. Evidence on the management and treatment of male breast cancer is scant. We report the analysis of a multicenter Italian series of patients with male breast cancer treated with eribulin. To our knowledge, this is the first report on the use or eribulin in this setting. Patients and Methods. Patients were retrospectively identified in 19 reference centers. All patients received eribulin treatment, according to the standard practice of each center. Data on the identified patients were collected using a standardized form and were then centrally reviewed by two experienced oncologists. Results. A total of 23 patients (median age, 64 yearsrange, 42–80) were considered. The median age at the time of diagnosis of breast cancerwas 57 years (range, 42–74).HER2 status was negative in 14 patients (61%), and 2 patients (9%) had triple-negative disease. The most common metastatic sites were the lung (n 5 1461%) and bone (n 5 1356%). Eribulin was administered for a median of 6 cycles (range, 3–15). All patients reported at least stable diseasetwo complete responses (9%) were documented. Eribulin was well-tolerated, with only four patients (17%) reporting grade 3 adverse events and two (9%) with treatment interruptions because of toxicity. Eight subjects (35%) did not report any adverse event during treatment. For patients with a reported fatal event, the median overall survival from the diagnosis of metastatic disease was 65 months (range, 22–228). Conclusion. Although hampered by all the limitations of any retrospective case series, the results of the present study suggest, for the first time, the use of eribulin as therapy for male breast cancer.
KW - Clinical practice
KW - Eribulin
KW - Male breast cancer
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=84995400081&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84995400081&partnerID=8YFLogxK
U2 - 10.1634/theoncologist.2016-0022
DO - 10.1634/theoncologist.2016-0022
M3 - Article
AN - SCOPUS:84995400081
VL - 21
SP - 1298
EP - 1305
JO - Oncologist
JF - Oncologist
SN - 1083-7159
IS - 11
ER -